Norges Bank’s Aprea Therapeutics APRE Stock Holding History

Norges Bank’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-750	Closed	-$688K	–	2051
2019 Q4	$688K	Buy	+750	New	+$413K	﹤0.01%	2039

Other funds holding APRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Norges Bank's APRE Position: Q1 2020 in Review

Norges Bank sold out of Aprea Therapeutics (APRE) in Q1 2020, closing a stake of 750 shares — an estimated $688K sold.

Norges Bank first reported a position in APRE in Q4 2019 and held it in 1 quarter. The position peaked at $688K in Q4 2019. 50 funds tracked by Wall St. Rank hold APRE as of Q1 2020.

Norges Bank reported no remaining Aprea Therapeutics position as of Q1 2020 after selling out during the quarter.
Norges Bank sold 750 Aprea Therapeutics shares in Q1 2020, an estimated $688K.
Norges Bank first reported a position in Aprea Therapeutics in Q4 2019 and held it in 1 quarter.
Norges Bank's Aprea Therapeutics position peaked at $688K in Q4 2019.
50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2020.

Based on Norges Bank's 13F filing for Q1 2020, filed 8 May 2020.